

TW9 biochemical

TW9

CATALOG #
AAA227109


PRODUCT SYNONYMS

TW9; TW9 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
Solubility	DMSO: 10 mg/mL DMF: 20 mg/mL <1mg/ml refers to the product slightly soluble or insoluble
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Mal-CO-PEG5-NHS ester, CAS 1232769-29-7



Structure
Mal-CO-PEG5-NHS ester, CAS 1232769-29-7

ADDITIONAL INFORMATION

Related Product Information for TW9 biochemical	TW9 is a dual inhibitor of bromodomain 2 (BD2) in bromodomain-containing protein 4 (BRD4) and histone deacetylase 1 (HDAC1; IC50s = 0.074 and 0.29 μ M, respectively). It is selective for BD2 over BD1 in BRD4 (IC50= 0.72 μ M) and for HDAC1 over HDAC2 (IC50= 2.5 μ M). TW9 (50 nM) induces apoptosis in, and inhibits proliferation of, MIA PaCa-2 pancreatic cancer cells. It induces cell cycle arrest at the G1phase in HPAC pancreatic cancer cells when used at a concentration of 2 μ M. TW9 acts synergistically with gemcitabine to reduce the viability of HPAC cells.
References	1. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

